FSD Pharma Inc. Announces $7.5 Million Dollar at $1 Per Share Investment as Part of Existing Strategic Alliance with Auxly Cannabis Group Inc.
TORONTO, Sept. 20, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) is pleased to announce that pursuant to the approved construction and development budget announced on July 3, 2018 (Link), Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly”) has made an equity investment into the Company at $1.00 per Class B Subordinate Voting Share for total proceeds of $7.5 million. No fees were paid to brokers in connection with the transaction.
FSD Pharma Signs Collaboration and Profit Sharing Agreement with Canntab for Production and Market of Oral Dose Delivery Platforms
TORONTO, Sept.18, 2018 /PRNewswire/ – FSD Pharma Inc. (CSE: HUGE) (OTC :FSDDF ) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the “Agreement”) with Canntab Therapeutics Limited (CSE:PILL) (“Canntab”), a leader in the rapidly growing cannabis pill market, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the “License”), and will provide Canntab with space at its facility (the “FSD Facility”), which is located just one hour east of Toronto in Cobourg, Ontario (the “Transaction”).
FSD Pharma joins Snipp’s Cannabis Marketing Resource Center
CSE: HUGE
OTC: FSDDF
FRA: 0K9
TORONTO, Sept. 17, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) today announced that it has joined the Cannabis Marketing Resource Center (“CMRC”) provided by Snipp Interactive Inc. (“Snipp”) (OTCQB: SNIPF; TSX-V: SPN), a global provider of digital marketing promotions, rebates and loyalty solutions. FSD has now joined some of the largest licensed producers in Canada that currently use the CMRC and the technology solutions provided by Snipp.
Continue Reading “FSD Pharma joins Snipp’s Cannabis Marketing Resource Center”
Bird River Resources Announces Conditional approval from the CSE
Winnipeg, Manitoba (FSCwire) – Bird River Resources Inc. (CSE:BDR) (the “Company”) is pleased to announce that further to its news release dated June 5, 2018 the Company has received conditional approval from the Canadian Securities Exchange (the “CSE”) for its draft comprehensive CSE Form 2A 2018 Listing Statement (“Listing Statement”) and lifting of the temporary trading halt on the Company’s shares. The draft Listing Statement has been prepared and filed pursuant to the request of the CSE for further information concerning the Company’s acquisition of High Point Oil Inc.
Continue Reading “Bird River Resources Announces Conditional approval from the CSE”
FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica
CSE: HUGE
OTC: FSDDF
FRA: 0K9
TORONTO, Sept. 13, 2018 /CNW/ – FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that it intends to launch a strategic partnership into the Jamaican cannabis market as part of its plan to expand internationally. FSD has signed a Letter of Intent (“LOI”) effective September 10, 2018 with JJAMACANN Inc. (“JJAMACANN”) to form a joint venture operating as FSD Jamaica (“FSD Jamaica”). FSD Jamaica expects to partner locally with Nature’s Purest Limited (“NPL”), a Jamaican corporation with a cultivation license and existing operations in Jamaica.
Continue Reading “FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica”
Ehave at the forefront of Canada’s medical cannabis transformation
Canada’s cannabis industry is poised for explosive growth, as the country is set to legalize marijuana nationwide in the summer by July of 2018. By 2024, more than 450,000 Canadian patients will be prescribed medical cannabis, creating a market worth more than $1.3 billion, according to Health Canada estimates.
Continue Reading “Ehave at the forefront of Canada’s medical cannabis transformation”
Canntab Therapeutics building cannabis delivery facility with FSD Pharma
Canntab Therapeutics Ltd (CSE:PILL) CEO Jeff Renwick and CFO Richard Goldstein tell Proactive Investor’s Christine Corrado the cannabis delivery manufacturing company is lining up its ducks ahead of the legalization of cannabis in Canada on October 17 this year – as it announced a profit sharing collaboration with medical pot producer FSD Pharma Inc.
Continue Reading “Canntab Therapeutics building cannabis delivery facility with FSD Pharma”